Understand the source comparison
SS-LUP-332 Safety Profile: Comparison Across Metabolic Modulators
The table below compares the published safety endpoints for SS-LUP-332 with two established metabolic research compounds—metformin (used as a reference standard in insulin sensitivity research) and SR9009 (a REV-ERB agonist with overlapping metabolic effects)—
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below compares the published safety endpoints for SS-LUP-332 with two established metabolic research compounds—metformin (used as a reference standard in insulin sensitivity research) and SR9009 (a REV-ERB agonist with overlapping metabolic effects)—to contextualize the current state of SS-LUP-332 safety data relative to compounds with more extensive toxicology profiles.
- | Compound | Acute LD50 (Oral, Mice) | Hepatotoxicity at Therapeutic Dose | Chronic Exposure Data (>12 Weeks) | Reproductive Toxicity Studies | Cardiovascular Safety Panel | Professional Assessment ||—|—|—|—|—|—|| SS-LUP-332 | >2000 mg/kg (Category 5, GHS) | No significant ALT/AST elevation at ≤30 mg/kg; mild ALT increase at 100 mg/kg in 28-day rat study | Not published; longest study duration is 28 days | Not published | Limited—telemetry and histology only, no echocardiography or stress testing | Favorable acute safety profile but lacks the chronic and multi-organ data needed for long-term research confidence. Best suited for pilot studies ≤8 weeks pending further validation. || Metformin | >1000 mg/kg (Category 4, GHS) | Minimal hepatotoxicity; rare cases of lactic acidosis in patients with renal impairment | Extensive—decades of clinical use with safety data up to 4+ years in humans | Established; no teratogenic effects in rodents or humans at therapeutic doses | Comprehensive—ECG